Craft

GeneDX

Stock Price

$6.9

2024-02-21

Market Capitalization

$179.9 M

2024-02-21

Revenue

$234.7 M

FY, 2022

GeneDX Summary

Company Summary

Overview
GeneDX Holdings (formerly Sema4 Holdings) is a health information company applying artificial intelligence (AI) and machine learning to clinical and genomic data. It develops Centrellis, a health intelligence platform for health data management and analytics. In addition, the company offers women’s health, hereditary cancer, biopharma, research, and testing solutions.
Type
Public
Status
Active
Founded
2017
HQ
Stamford, CT, US | view all locations
Website
https://ir.genedx.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Katherine Stueland

    Katherine Stueland, Chief Executive Officer and Board Member

  • Jennifer Brendel

    Jennifer Brendel, Chief Commercial Officer

  • Krish Ghosh

    Krish Ghosh, Chief Analytics Officer

  • Tony Prentice

    Tony Prentice, Chief Product Officer

Operating MetricsView all

Tests Performed Yearly (NGS)

250K

Q3, 2021

Data Managed per Month, petabytes

46

FY, 2021

De-identified Clinica Records in Database

12M

FY, 2021

LocationsView all

5 locations detected

  • Stamford, CT HQ

    United States

    333 Ludlow St Tower, 3rd floor

  • Branford, CT

    United States

    1 Commercial St

  • Gaithersburg, MD

    United States

    207 Perry Pkwy

  • New York, NY

    United States

    200 Park Ave S

  • Stamford, CT

    United States

    62 Southfield Ave

GeneDX Financials

Summary Financials

Revenue (Q3, 2023)
$53.3M
Gross profit (Q3, 2023)
$25.3M
Net income (Q3, 2023)
($42.3M)
Cash (Q3, 2023)
$87.4M
EBIT (Q3, 2023)
($43.0M)
Enterprise value
$98.8M

Footer menu